868 abstracts found.



Results filter

Identification of prognostic biomarkers for colorectal cancer

Year:

Session type:

Clare Foster, Naomi Willis, Joanne Robson, Christopher Hutchison

Durham University, UK


Needle oophropexy: a new simple technique for ovarian transposition prior to pelvic irradiation

Year:

Session type:

Waheed Gareer, Zeiad Gad

National Cancer Institute, Cairo University, Egypt


Aspirin, non-steroidal anti-inflammatory drug and paracetamol use is associated with an increased risk of prostate cancer in a large, population-based, case-control study

Year:

Session type:

Ali Murad1, Liz Down1, George Davey Smith1, Jenny Donovan1, Janet Athene Lane1, Freddie Hamdy2, David Neal3, Richard Martin1

1University of Bristol, UK, 2John Radcliffe Hospital, Oxford, UK, 3University of Cambridge, UK


Radiotherapy-related heart damage in breast cancer patients is predicted by cutaneous telangiectasiae

Year:

Session type:

Chris Talbot1, George Tanteles1, Irene Peat1, Ahmed Osman1, Gerry McCann2, Steve Chan3, Julian Barwell1, R. Paul Symonds1

1University of Leicester, UK, 2University Hospitals of Leicester, Glenfield Hospital, UK, 3Nottingham University Hospitals NHS Trust, UK


Lifestyle intervention improves functional capacity in men on androgen deprivation therapy for prostate cancer

Year:

Session type:

Liam Bourke1, Helen Crank1, Amanda Daley3, Derek Rosario2, John Saxton1

1Sheffield Hallam University, UK, 2University of Sheffield, UK, 3University of Birmingham, UK


A study of the relationship between drug efficacy/toxicity and platinum-DNA adduct formation in pre- and post-infusion lymphocyte samples from patients receiving platinum-based chemotherapy

Year:

Session type:

A L Thomas1, A Zayed2, J P Wood1, H Reid2, GDD Jones1, B L Sharp2

1University of Leicester, UK, 2Loughborough University, UK


Plasma phytanic acid concentration and risk of prostate cancer

Year:

Session type:

Alison Price, Naomi Allen, Timothy Key

University of Oxford, UK


Gemcitabine with or without prophylactic weight-adjusted Dalteparin (WAD) in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study)

Year:

Session type:

Anthony Maraveyas1, Justin Waters2, Rajarshi Roy3, David Propper4, David Fyfe5, Fiona Lofts6, Eric Gardiner1, Joseph Sgouros1, Kevin Wedgwood1

1The Queens Centre for Oncology & Hematology, Hull, UK, 2Kent Oncology Centre, Maidstone Hospital, UK, 3Diana Princess of Wales Hospital, Grimsby, UK, 4St Bartholomews Hospital,, London, UK, 5Royal Lancaster Infirmary, UK, 6St. Georges Hospital Medical School, London, UK


Investigating the link between diet and prostate cancer within the ProtecT trial

Year:

Session type:

Catherine Jameson1, Athene Lane1, Pauline Emmett1, Liz Down1, Marta Tazewell1, Steven Oliver4, Freddie Hamdy3, David Neal2, Jenny Donovan1

1University of Bristol, UK, 2Cambridge University Addenbrookes Hospital, UK, 3University of Oxford, UK, 4University of York, UK


Unplanned hospital admissions as an early surrogate indicator of patient (pt) attrition in phase I trials

Year:

Session type:

Saoirse Dolly

The Institute of Cancer Research, London, UK


Page 2 of 87« First...2...25...Last »